Wenxin Xu
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Wenxin Xu
Jun 9, 2024, 02:45 |
Insight
Brian Rini: KIM-1 is a novel prognostic and predictive biomarker in RCC
Toni Choueiri shared a post by Brian Rini, Chief of Clinical Trials at Vanderbilt University, on X/Twitter:…
Jun 1, 2024, 23:46 |
Blog
Wenxin Xu: AI models can accurately impute performance status from clinical notes
Wenxin Xu, Genitourinary oncologist and clinical cancer researcher at Dana-Farber Cancer Institute and Assistant Professor…
May 28, 2024, 07:49 |
Insight
Tom Powles: Renal cancer highlights at ASCO24 - KIM1 biomarker data stands out
Toni Choueiri shared a post by Tom Powles, Director of Barts Cancer Center, on X and…
May 12, 2024, 07:40 |
Insight
Yüksel Ürün: Excellent research on plasma Kidney Injury Molecule-1
Yüksel Ürün shared on X: "Congratulations to Wenxin Xu and the team for their excellent…
Sep 26, 2023, 18:38 |
Blog
Michael Serzan: Join a conversation The ASCO Post with Wenxin Xu and I as we dissect recent data to guide therapy!
Quoting Michael Serzan, Genitourinary Medical Oncologist at the Dana Farber Cancer Institute, on X/Twitter: “Few…
All:
5
Posts:
1 - 10
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
15 Posts You Should Not Miss From The 1st Day of ESMOGI24
Facebook
RSS Feed
Twitter
Linkedin
Youtube